Arietis
Arietis is a preclinical-stage antimicrobial company focused on discovery and optimization of small-molecule antibiotics that activate the ClpP protease to kill drug-resistant Gram‑positive pathogens and persistent/biofilm-associated infections. The organization applies structure‑guided medicinal chemistry, biophysical and biochemical assays, in vitro microbiology, pharmacokinetic/ADME optimization, hollow‑fiber pharmacodynamic modeling, and efficacy testing in predictive animal infection models. Arietis operates from a research facility on the Boston University medical campus and conducts collaborative development partnerships.
Industries
Nr. of Employees
small (1-50)
Products
Preclinical ClpP‑activating small‑molecule antibiotic candidates
Series of small‑molecule antibiotics designed to activate the ClpP protease and rapidly kill drug‑resistant Gram‑positive pathogens and biofilm/persister cell populations; advanced through in vitro screening, biophysical and biochemical assays, PK/ADME optimization, and in vivo efficacy models.
ADEP antibiotics
First-in-class small molecule antibiotics developed by Arietis that activate the ClpP protease to cause rapid and exceptional killing of highly resistant ESKAPE pathogens.
Preclinical ClpP‑activating small‑molecule antibiotic candidates
Series of small‑molecule antibiotics designed to activate the ClpP protease and rapidly kill drug‑resistant Gram‑positive pathogens and biofilm/persister cell populations; advanced through in vitro screening, biophysical and biochemical assays, PK/ADME optimization, and in vivo efficacy models.
ADEP antibiotics
First-in-class small molecule antibiotics developed by Arietis that activate the ClpP protease to cause rapid and exceptional killing of highly resistant ESKAPE pathogens.
Services
Partnerships and alliances to advance antimicrobial discovery programs and preclinical development.
Partnerships and alliances to advance antimicrobial discovery programs and preclinical development.
Expertise Areas
- Antimicrobial drug discovery
- Medicinal chemistry and SAR optimization
- Preclinical pharmacology and PK/PD
- Biophysical and biochemical assay development
Key Technologies
- ClpP protease activation
- Structure‑guided medicinal chemistry
- Peptide‑based synthetic chemistry
- Surface plasmon resonance (SPR)
News & Updates
Griffith EC et al. report on ureadepsipeptides as activators of ClpP protease.
Mroue N et al. describe pharmacodynamic evaluation of ClpP‑activating antibiotic combinations.
Conlon BP et al. demonstrate that activated ClpP can kill persister cells and eradicate chronic biofilm infection (Nature).
Griffith EC et al. report on ureadepsipeptides as activators of ClpP protease.
Mroue N et al. describe pharmacodynamic evaluation of ClpP‑activating antibiotic combinations.
Conlon BP et al. demonstrate that activated ClpP can kill persister cells and eradicate chronic biofilm infection (Nature).